SFG
VRTX icon

Strive Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Strive Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$261K Buy
525
+395
+304% +$175K 0.11% 120
2026
Q1 		$58K Buy
130
+17
+15% +$7.93K 0.03% 208
2025
Q4 		$51.2K Buy
+113
New +$48.7K 0.03% 218

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Strive Financial Group's VRTX Position: Q2 2026 in Review

Strive Financial Group increased its Vertex Pharmaceuticals (VRTX) stake by 304% in Q2 2026, buying an estimated $175K and bringing the position to 525 shares worth $261K. The position accounts for 0.11% of the portfolio, ranked #120.

Strive Financial Group first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Strive Financial Group held 525 shares of Vertex Pharmaceuticals worth $261K as of Q2 2026.
  • Strive Financial Group bought 395 Vertex Pharmaceuticals shares in Q2 2026, an estimated $175K.
  • Vertex Pharmaceuticals made up 0.11% of Strive Financial Group's portfolio in Q2 2026, its #120 holding.
  • Strive Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Strive Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.